M Arora

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. pmc Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis
    Mukta Arora
    Department of Hematology, Oncology and Transplant, University of Minnesota, 420 Delaware St SE, Minneapolis MN 55455, USA
    Blood 117:6714-20. 2011
  2. pmc Therapy of chronic graft-versus-host disease
    Mukta Arora
    Division of Hematology, Oncology and Transplantation, University of Minnesota, Mayo Mail Code 480, 420 Delaware Street SE, Minneapolis MN 55455, USA
    Best Pract Res Clin Haematol 21:271-9. 2008
  3. doi request reprint New classification of chronic GVHD: added clarity from the consensus diagnoses
    M Arora
    Blood and Marrow Transplant Program, Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:149-53. 2009
  4. ncbi request reprint Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB)
    Mukta Arora
    Blood and Marrow Transplant Program, Departments of Medicine and Pediatrics, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 13:1145-52. 2007
  5. pmc HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia
    Mukta Arora
    University of Minnesota, National Marrow Donor Program, Center for International Blood and Marrow Transplant Research, Minneapolis, MN 55455, USA
    J Clin Oncol 27:1644-52. 2009
  6. ncbi request reprint Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma
    M Arora
    Division of Hematology, Oncology and Transplantation, Department of Medicine, and the Blood and Marrow Transplant Program, University of Minnesota, MN 55455, USA
    Bone Marrow Transplant 35:1133-40. 2005
  7. pmc Polymorphisms in the base excision repair pathway and graft-versus-host disease
    M Arora
    Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Leukemia 24:1470-5. 2010
  8. pmc Impact of ABO-mismatch on risk of GVHD after umbilical cord blood transplantation
    R Romee
    Medicine, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 48:1046-9. 2013
  9. ncbi request reprint Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease
    M Arora
    Department of Medicine, University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 7:265-73. 2001
  10. ncbi request reprint Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial
    M Markova
    Blood and Marrow Transplantation Program, University of Minnesota, Minneapolis, MN, USA
    Bone Marrow Transplant 39:193-9. 2007

Detail Information

Publications32

  1. pmc Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis
    Mukta Arora
    Department of Hematology, Oncology and Transplant, University of Minnesota, 420 Delaware St SE, Minneapolis MN 55455, USA
    Blood 117:6714-20. 2011
    ..Validation of this cGVHD risk score is needed in a different population to ensure its broad applicability...
  2. pmc Therapy of chronic graft-versus-host disease
    Mukta Arora
    Division of Hematology, Oncology and Transplantation, University of Minnesota, Mayo Mail Code 480, 420 Delaware Street SE, Minneapolis MN 55455, USA
    Best Pract Res Clin Haematol 21:271-9. 2008
    ..A multidisciplinary approach to evaluating and managing patients with cGVHD is preferred, and disciplined, prospective study of new therapies is essential to make further progress in its understanding and treatment...
  3. doi request reprint New classification of chronic GVHD: added clarity from the consensus diagnoses
    M Arora
    Blood and Marrow Transplant Program, Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 43:149-53. 2009
    ..1% (95% CI 68-94)); P=0.1. This analysis, undertaken in a contemporary cohort of related donor recipients, indicates that the consensus guidelines are applicable to this population of CGVHD patients...
  4. ncbi request reprint Chronic graft-versus-host disease (cGVHD) following unrelated donor hematopoietic stem cell transplantation (HSCT): higher response rate in recipients of unrelated donor (URD) umbilical cord blood (UCB)
    Mukta Arora
    Blood and Marrow Transplant Program, Departments of Medicine and Pediatrics, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 13:1145-52. 2007
    ..In addition, progressive onset of cGVHD was a significant predictor of increased mortality in URD cohort. These data suggest that cGVHD following UCB transplant may be more responsive to therapy and also lead to a lower NRM...
  5. pmc HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia
    Mukta Arora
    University of Minnesota, National Marrow Donor Program, Center for International Blood and Marrow Transplant Research, Minneapolis, MN 55455, USA
    J Clin Oncol 27:1644-52. 2009
    ..However, the utility and outcome associated with transplants from URDs compared with those from MSDs remains undefined...
  6. ncbi request reprint Results of autologous and allogeneic hematopoietic cell transplant therapy for multiple myeloma
    M Arora
    Division of Hematology, Oncology and Transplantation, Department of Medicine, and the Blood and Marrow Transplant Program, University of Minnesota, MN 55455, USA
    Bone Marrow Transplant 35:1133-40. 2005
    ..Allogeneic HCT may be suitable in younger patients, soon after diagnosis, and in those with chemosensitive disease...
  7. pmc Polymorphisms in the base excision repair pathway and graft-versus-host disease
    M Arora
    Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Leukemia 24:1470-5. 2010
    ..81, 95% CI: 1.29-2.54, P=0.001). These results show that SNPs in the BER pathway can be used as genetic biomarkers to predict those at high risk for GVHD toward whom novel prophylactic strategies could be targeted...
  8. pmc Impact of ABO-mismatch on risk of GVHD after umbilical cord blood transplantation
    R Romee
    Medicine, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 48:1046-9. 2013
    ..Whereas ABO-compatible donors are preferred in recipients of URD-HCT, ABO compatibility generally need not be considered in recipients of UCB-HCT. ..
  9. ncbi request reprint Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease
    M Arora
    Department of Medicine, University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 7:265-73. 2001
    ..The value of thalidomide as salvage therapy requires further study...
  10. ncbi request reprint Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial
    M Markova
    Blood and Marrow Transplantation Program, University of Minnesota, Minneapolis, MN, USA
    Bone Marrow Transplant 39:193-9. 2007
    ..6 (95% CI 0.2-1.3) P=0.16) and with URD RR 0.4 (0.2-1.0) P=0.04). Older patients with advanced hematologic malignancies achieve satisfactory outcomes using either of these reduced intensity conditioning regimens...
  11. pmc Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome
    Michael B Tomblyn
    Department of Therapeutic Radiology and Radiation Oncology, University of Minnesota, Minneapolis, MN 55455, USA
    J Clin Oncol 27:3634-41. 2009
    ..Analysis of hematopoietic cell transplantation (HCT) for high-risk or recurrent acute lymphoblastic leukemia (ALL) using different donor sources is confounded by variable conditioning and supportive care...
  12. doi request reprint A modified comorbidity index for hematopoietic cell transplantation
    T E DeFor
    Biostatistics and Informatics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Bone Marrow Transplant 45:933-8. 2010
    ..In conclusion, we are introducing the MCI which may have higher discriminating and predictive power for overall survival and NRM. Validation of the HCT-CI and the MCI in larger and separate cohorts of HCT recipients is still needed...
  13. pmc Unrelated donor hematopoietic cell transplantation: factors associated with a better HLA match
    Jason Dehn
    National Marrow Donor Program, Minneapolis, Minnesota 55413 1753, USA
    Biol Blood Marrow Transplant 14:1334-40. 2008
    ....
  14. pmc Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia
    Theresa Hahn
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    J Clin Oncol 26:5728-34. 2008
    ..No large registry studies of acute GVHD risk factors have been reported in two decades. Risk factors may have changed in this interval as transplant-related techniques have evolved...
  15. pmc Association between genetic variants in adhesion molecules and outcomes after hematopoietic cell transplants
    B Thyagarajan
    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA
    Int J Immunogenet 40:108-15. 2013
    ..02). None of the SNPs were associated with acute or chronic GvHD risk. These findings suggest that genetic variants in the vascular adhesion molecules may be used to identify patients at high risk for TRM...
  16. ncbi request reprint Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis
    Catherine M Flynn
    Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota 55455, USA
    Am J Hematol 82:867-72. 2007
    ..Advances in GVHD management and new approaches for relapsed or refractory disease are necessary to improve these outcomes...
  17. pmc Higher therapeutic CsA levels early post transplantation reduce risk of acute GVHD and improves survival
    J R Rogosheske
    University of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN, USA
    Bone Marrow Transplant 49:122-5. 2014
    ..In patients who are near or even modestly above the CsA target trough level, in the absence of CsA-related toxicity, dose reduction should be cautious to avoid subtherapeutic drug levels resulting in higher risk of acute GVHD. ..
  18. pmc Why are urban Indian 6th graders using more tobacco than 8th graders? Findings from Project MYTRI
    M H Stigler
    Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA
    Tob Control 15:i54-60. 2006
    ..To investigate why urban Indian 6th graders may be using more tobacco than urban Indian 8th graders...
  19. ncbi request reprint Chronic graft-versus-host disease: a prospective cohort study
    Mukta Arora
    Department of Medicine, Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 9:38-45. 2003
    ..Recognition of a high-risk group should facilitate assignment of more intensified regimens. Better treatment regimens need to be identified to improve survival and limit toxicity of prolonged immunosuppression...
  20. pmc Association between genetic variants in the base excision repair pathway and outcomes after hematopoietic cell transplantations
    Bharat Thyagarajan
    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 16:1084-9. 2010
    ..These findings suggest that SNPs in the BER pathway can be used as genetic biomarkers to predict individuals at high risk for TRM and disease relapse. Modulation of pretransplant conditioning may alter risk in these patients...
  21. pmc Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse
    Daniel J Weisdorf
    University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 15:1475-8. 2009
    ..In this analysis, greater histoincompatibility can augment GVHD, but does not improve protection against relapse; thus the best donor remains the most closely matched donor...
  22. ncbi request reprint Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants
    Navneet S Majhail
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 14:985-92. 2008
    ..The HCT-CI, although a useful tool for capturing pretransplant comorbidity and risk-assessment, needs to be further validated prior to adopting it for routine clinical use...
  23. ncbi request reprint Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma
    Noel Laudi
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, USA
    Am J Hematol 81:519-24. 2006
    ..No autologous transplant-related deaths occurred. Allogeneic transplant-related mortality was 29% (95% CI 6-52%) at 1 and 5 years. HSCT for MCL can yield extended disease control and long-term survival...
  24. pmc Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study
    Christopher J Fraser
    Pediatric Blood and Marrow Transplant Program, Department of Pediatrics, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Blood 108:2867-73. 2006
    ..We conclude that active cGVHD has a significant impact on many aspects of the overall health status of HCT survivors and that, most importantly, those successfully treated for cGVHD do not appear to have long-term impairments...
  25. pmc Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor
    Navneet S Majhail
    Blood and Marrow Transplant Program, Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Biol Blood Marrow Transplant 14:282-9. 2008
    ..A careful review of existing comorbidities is necessary when considering older patients for HCT...
  26. pmc High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation
    N S Majhail
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA
    Bone Marrow Transplant 43:49-54. 2009
    ..We conclude that metabolic syndrome occurs frequently among allogeneic HCT survivors who are seen by transplant physicians. Approaches to screening, prevention and management of metabolic syndrome should be developed for HCT recipients...
  27. ncbi request reprint Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma
    Navneet S Majhail
    Blood and Marrow Transplant Program, Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 12:1065-72. 2006
    ..A risk-adapted approach should be followed in determining treatment options for patients with PR REF and REL HL...
  28. ncbi request reprint Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma
    Noel Laudi
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN 55455, USA
    Biol Blood Marrow Transplant 11:129-35. 2005
    ....
  29. ncbi request reprint Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma
    Mukta Arora
    Department of Medicine, University of Minnesota, Minneapolis 55455, USA
    Biol Blood Marrow Transplant 10:395-404. 2004
    ..Two cycles of priming chemotherapy plus autologous transplantation yields survival rates similar to those in published reports, including those using tandem transplantation...
  30. ncbi request reprint Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study
    Gorgun Akpek
    Department of Oncology, Johns Hopkins University, Baltimore, MD, USA
    Blood 102:802-9. 2003
    ..Although the new clinical grading based on the model is promising because of its utility across multiple independent data sets, prospective validation is needed...
  31. ncbi request reprint Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia
    Sergio A Giralt
    M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77230, USA
    Br J Haematol 137:461-7. 2007
    ..Most patients now receive a trial of imatinib before proceeding to HCT...
  32. pmc Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
    Stephanie J Lee
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 112:3500-7. 2008
    ..Acute graft-versus-host disease rates were similar between IM(+) and IM(-) groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT...